Follow the Pundits
Tag: Funanc1alInvesting
Rapid7 (RPD): Slow Growth, But Jana Sees Value & Institutions Are All In
Rapid7 (RPD) just caught hedge fund JANA Partners’ eye with a $15M insider buy. Institutions are piling in, but growth remains slow. Is this a value gem in cybersecurity or just another trap? We break it down with humor, icons, and insights.
Bill Ackman’s Pershing Square Still Noshes on Restaurant Brands International (QSR). Should You?
Restaurant Brands International ($QSR) is cooking up dividends, international growth, and a massive Burger King reset. Bill Ackman’s Pershing Square still owns a super-sized stake—should you follow suit, or wait for a dip before ordering?
Bill Ackman’s Pershing Square Still Hearts Brookfield (BN)
Bill Ackman still loves Brookfield, his top Pershing Square bet—now up 39%! But at nearly $68 per share, has the value vanished? We dig into insider buying, institutional interest, financial highlights, and whether this former bargain is still a buy. 💼📈
Cathie Wood’s Ark Bought More Teradyne (TER)… Should You?
Cathie Wood is doubling down on Teradyne, a robotics and semiconductor test powerhouse with a $1B buyback plan and big AI dreams. Should investors follow? Our fun, fact-filled breakdown has you covered.
Paul Tudor Jones Loves IWM. Should You?
Paul Tudor Jones is going heavy on small caps—and maybe prepping for AI-induced doom. With 1,350+ positions and an options playbook that could fill a library, what’s his real bet? And more importantly: should you follow? Read on, but don’t YOLO.
ACADIA Pharmaceuticals: Biotech Powerhouse Baker Bros Still Believes. Should You Buy In?
Biotech heavyweight Baker Bros still owns over 25% of ACADIA Pharmaceuticals (ACAD), and the stock is heating up. With expanding revenue, a rich CNS pipeline, and smart money backing it, is this the comeback story investors have been waiting for?
John Paulson Is Loading Up on Perpetua Resources. Should You?
John Paulson knows a good discount when he sees one—and he just grabbed another $100M worth of Perpetua Resources (PPTA). But what is this gold-and-antimony play really about? From Idaho mines to strategic minerals and a wink at squirrel invasions, we break it all down.
Bausch Health: Paulson Doubles Down, Stock Breaks Out, Recovery Accelerates
Bausch Health ($BHC) is back in the spotlight as legendary investor John Paulson adds millions more in shares, fueling a breakout rally. With Q2 earnings showing revenue growth, profit rebound, and debt repayment plans, could BHC be staging its long-awaited comeback?
Apple Remains Warren Buffett’s Top Stock — Should You Still Bite?
Buffett’s got $60 billion riding on Apple. Services are booming. iPhone addiction remains. But is it still worth your bite — or should you wait for a sweeter dip? 🍏🤔
Daniel Loeb Still Thinks PG&E Stands for Purchase, Grab & Enjoy
PG&E has gone from fiery headlines to financial footing—and Daniel Loeb’s Third Point is all-in. With 14% of his portfolio riding on PCG, a growing customer base, and wildfire risks contained (for now), is this survivor stock worth a second look?
2 comments
|